Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Julie R. Park et al.|Clinical Cancer Research|2018Cited by 88
Sorbitol Is a Severity Biomarker for <scp>PMM2‐CDG</scp> with Therapeutic ImplicationsAnna N. Ligezka, Éva Morava, Ethan Perlstein et al.|Annals of Neurology|2021Cited by 57